Technical Analysis for ZYNE - Zynerba Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
D 4.54 1.79% 0.08
ZYNE closed up 3.96 percent on Friday, May 14, 2021, on 67 percent of normal volume.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Down Up
Historical ZYNE trend table...

Date Alert Name Type % Chg
20 DMA Support Bullish 1.79%
Inside Day Range Contraction 1.79%
Up 3 Days in a Row Strength 1.79%
50 DMA Resistance Bearish 5.83%
Crossed Above 20 DMA Bullish 5.83%
20 DMA Resistance Bearish 7.08%
50 DMA Resistance Bearish 7.08%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 7.08%
Inside Day Range Contraction 7.08%
20 DMA Resistance Bearish 9.13%
Older End-of-Day Signals for ZYNE ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
10 DMA Support about 1 hour ago
Up 2% about 2 hours ago
50 DMA Resistance about 3 hours ago
Rose Above 50 DMA about 3 hours ago
Up 1% about 3 hours ago
View Earlier Intraday Alerts

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Zynerba Pharmaceuticals, Inc. Description

Zynerba Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company is focused on developing and commercializing synthetic cannabinoid therapeutics formulated for transdermal delivery. The Company has two product candidates, including ZYN002 and ZYN001, which represent cannabinoid therapeutics for several indications, including refractory epilepsy, Fragile X syndrome (FXS), osteoarthritis (OA), fibromyalgia and peripheral neuropathic pain. ZYN002 is a synthetic cannabidiol (CBD) formulated as a permeation-enhanced gel for transdermal delivery. In preclinical animal studies, ZYN002's permeation enhancer increased delivery of CBD through the layers of the skin and into the circulatory system. ZYN001 is a pro-drug of delta-9-tetrahydrocannabinol (THC) that enables transdermal delivery through a patch. In preclinical animal studies, ZYN001 demonstrated effective skin permeation with sustained delivery and rapid conversion of ZYN001 to THC.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Pharmaceutical Pain Drugs Chemical Compounds Psychoactive Drugs Entheogens Osteoarthritis Epilepsy Neuropathic Pain Circulatory System Transdermal Cannabidiol Cannabinoid Fibromyalgia Cannabinoids CBD Fragile X Syndrome Cannabinol

Is ZYNE a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 9.0
52 Week Low 3.12
Average Volume 1,760,134
200-Day Moving Average 4.08
50-Day Moving Average 4.50
20-Day Moving Average 4.29
10-Day Moving Average 4.28
Average True Range 0.39
ADX 13.35
+DI 17.34
-DI 12.72
Chandelier Exit (Long, 3 ATRs ) 3.62
Chandelier Exit (Short, 3 ATRs ) 4.85
Upper Bollinger Band 4.72
Lower Bollinger Band 3.86
Percent B (%b) 0.7
BandWidth 20.02
MACD Line -0.04
MACD Signal Line -0.06
MACD Histogram 0.0209
Fundamentals Value
Market Cap 131.3 Million
Num Shares 29.4 Million
EPS -1.89
Price-to-Earnings (P/E) Ratio -2.36
Price-to-Sales 1152.69
Price-to-Book 1.97
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 4.82
Resistance 3 (R3) 4.79 4.64 4.76
Resistance 2 (R2) 4.64 4.55 4.66 4.74
Resistance 1 (R1) 4.55 4.49 4.60 4.58 4.72
Pivot Point 4.40 4.40 4.42 4.42 4.40
Support 1 (S1) 4.31 4.31 4.36 4.34 4.20
Support 2 (S2) 4.16 4.25 4.18 4.18
Support 3 (S3) 4.07 4.16 4.16
Support 4 (S4) 4.10